Everything below concerns GHK-Cu. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-20. Numbers and descriptions here follow the published literature rather than marketing material.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
For outside planting, USDA Zone 9 or higher is recommended. In nature, Mimosa tenuiflora "[...] fruits and seeds are disseminated by the wind in a radius of 5–8 m (16–26 ft) from the mother plant; rain carries them from slopes to lower plains and human activities contribute to their dissemination." For cultivation, the seed pods are collected once they start to spontaneously open on the tree. The collected pods are laid out in the sun so that the pods open up and release their seeds. The seeds can then be planted in sandy soil with sun exposure. Scarification of the seed via mechanical means or by using sulfuric acid greatly increases the germination rate of the seeds over non-treatment. The seeds can be sown directly into holes in the ground or planted in prepared areas. The seeds can germinate in temperatures ranging from 10 to 30 °C, but the highest germination rate occurs at around 25 °C (about 96%), even after four years of storage. Germination takes about 2–4 weeks. It is also possible to propagate Mimosa tenuiflora via cuttings. Trimming adult Mimosa tenuiflora during the rainy season is not recommended as it can kill them.
=== Laminin EGF-like === Beside different types of globular domains each laminin subunit contains, in its first half, consecutive repeats of about 60 amino acids in length that include eight conserved cysteines. The tertiary structure of this domain is remotely similar in its N-terminus to that of the EGF-like module. It is also known as a 'LE' or 'laminin-type EGF-like' domain. The number of copies of the laminin EGF-like domain in the different forms of laminins is highly variable; from 3 up to 22 copies have been found. In mouse laminin gamma-1 chain, the seventh LE domain has been shown to be the only one that binds with a high affinity to nidogen. The binding-sites are located on the surface within the loops C1-C3 and C5-C6. Long consecutive arrays of laminin EGF-like domains in laminins form rod-like elements of limited flexibility, which determine the spacing in the formation of laminin networks of basement membranes.
hydrogen bond A form of electrostatic interaction between an electronegative atom and a hydrogen atom bound to a second electronegative atom. Hydrogen bonding is unique because the small size of the hydrogen atoms permits proximity of the interacting electrical charges, and may occur as an intermolecular or intramolecular force.
18 August – Researchers in Austria propose coupling an electron microscope to a trapped-ion quantum computer, allowing quantum information from successive electrons to be combined and potentially enabling high-resolution imaging with fewer electrons, reducing damage to sensitive samples. 19 August – Astronomers report the discovery of S301, the closest and fastest star yet observed orbiting Sagittarius A*, the supermassive black hole at the centre of the Milky Way. The star completes an orbit every 8.7 years and reaches about 25,000 km/s, or 8.5% of the speed of light, at its closest approach. Its unusually tight orbit may enable a direct measurement of Sagittarius A*'s spin within about a decade. 23 August – A review published in Global Challenges finds that no place on Earth is resilient to all of the major global catastrophic risks considered. Australia shows resilience across the widest range of scenarios, while geographic isolation, food self-sufficiency, high-quality governance and decentralisation emerge as recurring resilience factors. 26 August University College London reports that London neurosurgeons have performed the first AI-assisted brain surgery at the National Hospital for Neurology and Neurosurgery in a 48-year-old patient who was diagnosed with a brain tumour in 2024. The U.S. Food and Drug Administration approves the RAS inhibitor drug daraxonrasib as a treatment for metastatic pancreatic cancer. 30 August – NASA launches the flagship Nancy Grace Roman Space Telescope aboard a SpaceX Falcon Heavy rocket from the Kennedy Space Center in Florida.
The ASCP Board of Registry (BOR) was established in 1928 as the "Registration Bureau for Technicians" as the first certification agency for clinical laboratory personnel in the US. ASCP was the first professional medical organization to set standards for laboratory professionals, which initially only required a recommendation from a member. Those recommended were subsequently registered with ASCP, hence name the Board of Registry. In 1931, there were two classifications for registrants: Laboratory Technician (L.T.) and Medical Technologist (M.T.). The L.T. designation was granted to all technicians who met the minimum requirements without the examination. The M.T. designations was issued to applicants who met rigid requirement of the Board and were individually elected at each annual meeting. The first certification was issued in 1930 to Paul H. Adams of Fort Wayne, Indiana. In 1933, ASCP began to assess individuals for academic and clinical prerequisites, and those who passed a board examination were granted certification. The initial certifications included a written and practical component. In 1935 the title Medical Technologist (MT) automatically to those certified Laboratory Technicians with college degrees. In 1936, the "Laboratory Technician" designation is retired and subsequent registrants are designated Medical Technologists and the academic requirements were raised to two years of college. In 1938, the Registry was renamed from the Registry of Technicians to the Registry of Medical Technologists.
Sources: en.wikipedia.org
The other common method for introducing the Fmoc group is through 9-fluorenylmethylsuccinimidyl carbonate (Fmoc-OSu), which may itself be obtained by the reaction of Fmoc-Cl with the dicyclohexylammonium salt of N-hydroxysuccinimide. Reacting with 9-fluorenylmethyloxycarbonyl azide (itself made by reacting Fmoc-Cl with sodium azide) in sodium bicarbonate and aqueous dioxane is also a method to install Fmoc group. Because the fluorenyl group is highly fluorescent, certain UV-inactive compounds may be reacted to give the Fmoc derivatives, suitable for analysis by reversed phase HPLC. Analytical uses of Fmoc-Cl that do not use chromatography may be limited by the requirement that excess Fmoc-Cl be removed before an analysis of fluorescence.
Barnum Brown, assistant curator of the American Museum of Natural History, found the first partial skeleton of T. rex in eastern Wyoming in 1900. Brown found another partial skeleton in the Hell Creek Formation in Montana in 1902, comprising approximately 34 fossilized bones. Writing at the time Brown said "Quarry No. 1 contains the femur, pubes, humerus, three vertebrae and two undetermined bones of a large Carnivorous Dinosaur not described by Marsh. ... I have never seen anything like it from the Cretaceous." Henry Fairfield Osborn, president of the American Museum of Natural History, named the second skeleton T. rex in 1905. The generic name is derived from the Greek words τύραννος (tyrannos, meaning "tyrant") and σαῦρος (sauros, meaning "lizard"). Osborn used the Latin word rex, meaning "king", for the specific name. The full binomial therefore translates to "tyrant lizard the king" or "King Tyrant Lizard", emphasizing the animal's size and presumed dominance over other species of the time.
=== On nuclear factor kappa B === Certain poloxamers such as P85 have been shown not only to be able to transport target genes to target cells, but also to increase gene expression. Certain poloxamers, such as P85 and L61, have also been shown to stimulate transcription of NF kappaB genes, although the mechanism by which this is achieved is currently unknown, bar that P85 has been shown to induce phosphorylation of the inhibitory kappa.
=== Duration of treatment === The optimal duration of add-on trastuzumab treatment after surgery for early breast cancer is unknown. One year of treatment is generally accepted based on clinical trial evidence that demonstrated the superiority of one-year treatment over none. However, a small Finnish trial also showed similar improvement with nine weeks of treatment over no therapy. Because of the lack of direct head-to-head comparison in clinical trials, it is unknown whether a shorter duration of treatment may be just as effective (with fewer side effects) than the accepted practice of treatment for one year. Debate about treatment duration has become a relevant issue for many public health policy makers because administering trastuzumab for a year is very expensive. Consequently, some countries with a taxpayer-funded public health system, such as New Zealand, chose to fund limited adjuvant therapy. However, subsequently New Zealand has revised its policy and now funds trastuzumab treatment for up to 12 months.
Sources: en.wikipedia.org
Bioreference Laboratories, a clinical laboratory with a core genetic testing business The 4K Test Score, a blood test for prostate cancer Pharmaceutical development, with products such as Rayaldee Varubi, a chemotherapy inducted nausea medication As of 2024, the chairman and CEO of OPKO is Phillip Frost. In May 2022, OPKO Health announced the acquisition for $300 million of U.S. based Biotechnology firm, ModeX. With it OPKO gained proprietary immunotherapy technology for infectious diseases and oncology.
Heroin-assisted treatment (HAT), or diamorphine-assisted treatment, refers to a type of Medication-Assisted Treatment (MAT) where semi-synthetic heroin is prescribed to opioid addicts who do not benefit from, or cannot tolerate, treatment with one of the established drugs used in opioid replacement therapy such as methadone or buprenorphine/naloxone (brand name Suboxone). For this group of patients, heroin-assisted treatment has proven superior in improving their social and health situation. Heroin-assisted treatment is fully a part of the national health system in Switzerland, Germany, the Netherlands, Canada, and Denmark. Additional trials are being carried out in the United Kingdom, Norway, and Belgium.
== Tailored vaccination strategies == During a pandemic wave, rapid vaccination of those driving virus dissemination (the socially active) and vaccination of those at highest risk (the elderly, often socially less active) are two desirable goals that are at odds in the setting of limited vaccine supply. However, the recent study (published in 2022) on the national COVID-19 vaccination schedules in 29 countries (EU, UK, and Israel) shows that all researched schedules prioritized criteria referring to higher risk (being over 65 years old and/or having coexisting health conditions) over the criteria referring to virus dissemination (occupation and/or housing conditions). Postponing a second vaccine dose (the first is more important for avoiding a severe disease course) to allow faster access to the first dose for more persons has been chosen as deployment strategies in some countries. Using a reduced mRNA vaccine dose in the younger, who have a lower disease risk, a stronger immune response to the vaccination but are key drivers of pandemic waves, may allow reaching more persons faster, with vaccination strategy models predicting a significant reduction of nation-wide case load and deaths. On the other side, protection of some groups, e.g. the elderly or the immunosuppressed may require additional booster doses.
=== Pharmacokinetics === Bemethyl resists metabolization and is long-lived, accumulating in tissues over course of treatment. In one study involving rats, long-term administration of Bemethyl was accompanied by a 1.38-fold increase in drug concentration in the brain, and a 1.68-fold increase in its concentration in skeletal muscles.
== See also == Air Force Specialty Code Badges of the United States Army United States Army branch insignia List of United States Coast Guard ratings List of United States Marine Corps MOS List of United States Naval officer designators List of United States Navy ratings List of United States Navy staff corps
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
It is a complex of the tripeptide glycyl-L-histidyl-L-lysine with a copper(II) ion. The peptide coordinates the metal through its histidine, amino terminus, and an amide nitrogen. It is often listed simply as copper tripeptide-1.